More on RGNX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.17 |
|
|||
| Open | $7.03 | ||||
| 52 Wk High | $25.00 | ||||
| 52 Wk Low | $7.07 | ||||
| Day High | $7.08 | ||||
| Day Low | $6.63 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,452,353 | ||||
- Kenneth T. Mills resigns from Regenxbio board
- Form 8-K REGENXBIO Inc. For: Oct 14
- Form SCHEDULE 13G REGENXBIO Inc. Filed by: JPMORGAN CHASE & CO
- REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
- Mizuho Starts Regenxbio Inc. (RGNX) at Outperform
- H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
- Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
- Regenxbio stock gains on positive gene therapy trial data
- REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
- Regenxbio settles patent dispute with Sarepta for $39M
Entities mentioned with RGNX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Definitive Agreement | View Related Stories »
- Morgan Stanley | View Related Stories »
- 13G | View Related Stories »
- Show More...
